http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1166610-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5922cbe7c65a9136f85906fa09e7c967 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J71-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J75-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J75-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00 |
| filingDate | 1967-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1969-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1166610-A |
| titleOfInvention | Improvements in or relating to 16alpha,17alpha-Ethylene and Substituted Ethylene[3,2-c]Pyrazolo-Steroids |
| abstract | 1,166,610. 16α,17α-Ethylene and substituted ethylene[3,2-c]pyrazolosteroids. SYNTEX CORP. 25 Jan., 1967 [1 Feb., 1966], No. 3761/67. Heading C2U. Novel steroids of the formula (wherein Z is a single or double bond or a 6α,7α- CXY group, X and Y being H, Cl or F; R<SP>1</SP> is H, F or Cl; R<SP>2</SP> is H, Cl, F or CH 3 ; R<SP>3</SP> is H or Ph which may be F, NO 2 or OCH 3 substituted; R<SP>4</SP> is H, PO(OH) 2 , tetrahydropyranyl, or a hydrocarbon carboxylic acyl group of less than 12 carbon atoms which is optionally substituted; R<SP>5</SP> is OH or Cl, R<SP>1</SP> being Cl when R<SP>5</SP> is Cl; A and B are H, Cl, F, or C 1-4 alkyl; and D and E are H, Cl, F, Ph, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 acyloxy or C 1 _ 4 haloalkyl; or A and B or D and E together are CH 2 or CF 2 ) are prepared from the corresponding #<SP>4</SP>-3-keto-steroids via their 2- hydroxymethylene derivatives by reaction of the latter with hydrazine or substituted hydrazines, the 21-OH group being temporarily protected e.g. as the tetrahydropyranyl ether. The 21-esters are prepared from the 21-ols by direct esterification or, in the case of the 21- phosphates, via the 21-mesylpxy and 21-iodo compounds. Starting materials of the formula are prepared by the methods disclosed in Specification 1,166,609, via the corresponding 3- keto- #<SP>4</SP>,<SP>16</SP> - dienes and the corresponding #<SP>5</SP>,<SP>16</SP>- 3 - ketals. In one preparation 11# - hydroxy- 17α,20; 20,21 - bismethylenediozypregn - 4 - en- 3-one (prepared from the free 17α,21-diol-20- one) is converted to the corresponding 4,6-diene, this is converted to the #<SP>4</SP> - 6α,7α - difluoromethylene compound, this is hydrolysed to 6α,7α- difluoromethylene - 11#,17α,21 - trihydroxypregn - 4 - ene - 3,20 - dione, this is converted to the 21-acetate, this to its 3,20-bissemicarbazone and this to 6α,7α-difluoromethylene-11#-hydroxy - 21 - acetoxypregna - 4,16 - diene - 3,20- dione. Similarly 9α - fluoro - 11#,17α - dihydroxy - 21 - acetoxypregn - 4 - ene 3,20- dione 3,20-bissemicarbazone is used in the preparation of the corresponding 4,16-diene. The steroids of the invention, which are stated to possess corticoid and anti-inflammatory properties, may be made up into pharmaceutical compositions. |
| priorityDate | 1966-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.